The Cabenuva (cabotegravir and rilpivirine) injection was discovered to be effective in dealing with the Acquired Immune Deficiency Syndrome (AIDS) virus and will be administered to adults diagnosed with HIV.
Approved by the United States’ Food and Drug Administration (FDA), the injection comprises of cabotegravir, rilpivirine and is the first and only complete long-acting regimen for HIV treatment.
The injectable complete regimen is administered once a month as opposed to the daily antiretroviral pills.
According to the director of the Office of Infections and Diseases in the FDA’s Centre for Evaluation and Research, John Farley, patients will have an option to choose from the daily oral treatment regimen and the monthly injections.
The agency also approved a pill version of cabotegravir to be taken with rilpivarine for a month before switching to the shots to be sure the drugs are well tolerated.
“Even people who are taking one pill a day just reported improvement in their quality of life to switch to an injection,” said Dr. Judith Currier, an HIV specialist at the University of California, Los Angeles.
The approval of Cabenuva is based on the pivotal phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies that included more than 1,100 patients from 16 countries.